Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG BIIB NFLX IBB AMZN TSLA ILMN ALXN AMGN CHTR WYNN COST GMCR SIAL VRTX SLXP CELG WDC SBAC
Nyse: ACT V LNKD PPG AGN MCK IVV GS LMT SPG FDX MMM IBM PXD NOC TWC APD HUM CMI GD
New Highs: SHW EQIX PPG IVV LMT ORLY SPG AVB MMM NOC HSIC RCPT BXP LLL PANW VNO HAIN KMB UPS RTN

The Hot Industries

Specialty Chemicals 2
Aerospace/Defense Products & Services 2
Networking & Communication Devices 1

The Hot Sectors

Financial 4
Industrial Goods 4
Services 4

SPPI Stock Chart


SPPI
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

N/A
Monthly

Website:

http://www.sppirx.com

SPPI Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc., a biotechnology company, develops and commercializes oncology and hematology drug products. The company’s commercialized drug products include FUSILEV for the treatment of patients with metastatic colorectal cancer, rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; ZEVALIN injection for intravenous use as a prescription medication; and MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation of the anticancer drug vincristine for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. It also develops BELEODAQ for the treatment of various hematological and solid tumors; Captisol-enabled MELPHALAN, an intravenous formulation of MELPHALAN for clinicians and patients in the multiple myeloma transplant setting; APAZIQUONE to treat non-muscle invasive bladder cancer; and SPI-2012 for the treatment of chemotherapy-induced neutropenia. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe and Japan. It has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan; collaboration agreement with Nippon Kayaku Co., Ltd.; licensing and collaboration agreement with TopoTarget A/S; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.